← Back to patent-cliff list
JMKX-000197
Tier C — Watch / tradeJMKX-000197
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：STING
Indications (approved)：恶性胸腔积液, Bladder cancer, Solid tumour
Regional status
US
Phase I
2023-12-12
EU
-
China
Phase II
2026-06-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JMKX-000197?
Approved indications include: 恶性胸腔积液, Bladder cancer, Solid tumour.
When does the JMKX-000197 patent expire?
No public expiry year is available for JMKX-000197 yet; this page updates once verified.
How do I get a quote for JMKX-000197 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29